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Background: Uveal melanoma is the most common primary intraocular malignancy in adults. Despite successful
control of the primary tumor, metastatic disease will ultimately develop in approximately 50% of patients, with the
liver being the most common site for metastases. The median survival for patients with liver metastases is between
6 and 12 months, and no treatment has in randomized trials ever been shown to prolong survival. A previous
phase II trial using isolated hepatic perfusion (IHP) has suggested a 14-month increase in overall survival compared
with a historic control group consisting of the longest surviving patients in Sweden during the same time period
(26 versus 12 months).
Methods/Design: This is the protocol for a multicenter phase III trial randomizing patients with isolated liver
metastases of uveal melanoma to IHP or best alternative care (BAC). Inclusion criteria include liver metastases (verified
by biopsy) and no evidence of extra-hepatic tumor manifestations by positron emission tomography–computed
tomography (PET-CT). The primary endpoint is overall survival at 24 months, with secondary endpoints including
response rate, progression-free survival, and quality of life. The planned sample size is 78 patients throughout
five years.
Discussion: Patients with isolated liver metastases of uveal melanoma origin have a short expected survival and
no standard treatment option exists. This is the first randomized clinical trial to evaluate IHP as a treatment option
with overall survival being the primary endpoint.
Trial registration: ClinicalTrials.gov registration number: NCT01785316 (registered 1 February 2013). EudraCT
registration number: 2013-000564-29.
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Uveal melanoma is the most common primary intraocular
malignancy in adults. Despite successful control of the pri-
mary tumor, patients with uveal melanoma have a high
risk of developing metastatic disease. In the Collaborative
Ocular Melanoma Study (COMS), the cumulative five
and 10-year rates were 25% and 34% respectively [1].* Correspondence: roger.olofsson@surgery.gu.se
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unless otherwise stated.Moreover, late metastases are frequent, with approxi-
mately 50% of the patients ultimately developing metasta-
ses [2]. The liver is the most common site for metastases
and about 50% of the patients with advanced disease will
have isolated liver metastases. These metastases are gener-
ally refractory to systemic chemotherapy and the median
survival for patients with liver metastases is about six
months. Regardless of treatment, the mortality rate is
approximately 90% at two years with only about 1% of
patients surviving more than five years [1].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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any prolonged survival. Dacarbazine and temozolomide
[3], as well as different multidrug regimens such as gemci-
tabine together with treosulfan [4], or the BOLD regimen
(bleomycin, vincristine, lomustine, and dacarbazine) [5],
have reported response rates of less than 10%. There are
also reports of newer drugs which have proven efficacy in
cutaneous malignant melanoma. At the 2013 American
Society of Clinical Oncology (ASCO) meeting a random-
ized trial comparing the mitogen-activated protein kinase
kinase (MEK) inhibitor selumetinib and temozolomide
was reported. The trial included 80 patients and the
results showed a response rate of 15% for selumetinib and
a significant increase in progression-free survival (PFS) in
nine weeks [6]. Two small trials have been published
evaluating the efficacy and safety of ipilimumab in the
treatment of metastatic uveal melanoma. The response
rates have been low, with one partial response (PR) and
three stable disease (SD) in a total of 35 patients. The
median survival was reported to be nine months and
five months respectively in the two trials [7,8]. Currently,
there are several phase I and II clinical trials evaluating
the potential effects of new targeted therapies, either in
monotherapy or in different combinations. The trials in-
clude trametinib (MEK-inhibitor), AEB001 (protein kinase
C inhibitor), BVD-523 (extracellular signal-related kinase
(ERK) inhibitor), and GSK2141795 (protein kinase B (AKT)
inhibitor).
For patients with isolated liver metastases several dif-
ferent loco-regional liver treatment strategies have
been explored. A retrospective study by Mariani et al.
analyzed 3873 patients with uveal melanoma, of these
798 developed liver metastases, and 255 patients later
underwent surgical resection with an overall survival
(OS) of 14 months [9]. In the highly selected group of
76 patients where a R0 resection was achieved, a median
overall survival of 27 months was reported. The European
Organisation for Research and Treatment of Cancer
(EORTC) 18021 study compared hepatic intra-arterial
chemotherapy (HIA) with systemic chemotherapy and
showed a modest increase in overall response rate for
HIA (12 versus 2%), but no significant improvement in
OS [10]. Transarterial chemoembolization (TACE) con-
sists of a hepatic artery embolization with a simultaneous
infusion of concentrated doses of a chemotherapeutic
drug. Huppert et al. reported the results of TACE with
cisplatin or carboplatin in 14 patients with uveal melan-
oma and liver metastases. Eight patients (57%) achieved a
PR, four patients (29%) were assessed as SD, and two pa-
tients (14%) experienced tumor progression. Median time
to progression was nine months and median survival was
12 months [11]. Selective internal radiation therapy
(SIRT), mostly using the beta-emitting isotope Yttrium-90,
has been used to deliver high-dose radiation to hepaticmetastases. In a study by Klingenstein et al., 13 patients
underwent SIRT, resulting in PR in eight patients (62%)
and SD in two patients (15%) with a median survival time
of seven months [12].
Isolated hepatic perfusion (IHP) is a regional treatment
that was first performed more than 40 years ago [13].
During IHP, the liver is completely isolated from the
systemic circulation, allowing a high concentration of
chemotherapy to be perfused through the liver with
minimal systemic exposure. In a previous study from
our institution, improvements in the IHP procedure
resulted in, minimized morbidity and mortality over
time [14]. A phase II follow-up study confirms that
IHP is a promising technique with tolerable morbidity
[15]. There are currently no randomized trials using
IHP, but in an attempt to find out whether the treat-
ment prolongs OS we did a register study. The study
showed a 14-month increased survival (26 versus
12 months) when comparing patients treated with IHP
with the longest surviving patients in Sweden during
the same time period [15].
In the early 1990s, three independent groups devel-
oped the percutaneous hepatic perfusion (PHP) tech-
nique combining a conventional hepatic artery infusion
with a dual-balloon vena cava catheter collecting the
outflow from the liver. The venous outflow was then
connected to an extracorporeal venous bypass circuit,
including a carbon filter, to recover any of the drug that
was not absorbed by the liver [16-18]. A phase III study
randomized 93 patients to either PHP or best alternative
care (BAC). There was a significant increase in the
primary endpoint, hepatic PFS (245 versus 49 days), and
also in the overall response (34 versus 2%). Any conclu-
sions concerning OS in this study are difficult to make
due to the high proportion of patients crossing over
from BAC to PHP [19].
In summary, many different treatment strategies have
been explored for patients with liver metastases from
uveal melanoma, but no one strategy has yet been proven
to yield a survival benefit. The aim of this randomized
study is to evaluate if IHP increases OS compared with
BAC in patients with isolated liver metastases from uveal
melanoma.
Methods/Design
This is a prospective multicenter trial planning to
randomize 78 patients to either IHP or BAC in a 1:1 ra-
tio. The inclusion and exclusion criteria are depicted in
Table 1. Randomization will be performed using permu-
tated blocks with variable size stratified for study site.
The study was approved by the Regional Ethical Review
Board at the University of Gothenburg (reference num-
ber: 144–13), and all patients will provide written in-
formed consent before inclusion in the trial.
Table 1 Inclusion and exclusion criteria
Inclusion criteria
1. Male or female aged above 18 years.
2. Signed and dated written informed consent before the start
of specific protocol procedures.
3. Liver metastases measurable by magnetic resonance imaging
(MRI, preferred) or a computational tomography (CT) scan of
thorax and abdomen according to RECIST version 1.1 with at
least one unidimensional measurable lesion≥ 10 mm. The
examination should be within four weeks prior to
randomization.
4. ECOG performance status of 0 or 1.
5. No previous chemotherapy, radiotherapy, or biologic therapy
for uveal melanoma metastases (first-line therapy)
6. Adequate hepatic function (defined as ASAT,ALAT, bilirubin
< = 3*ULN and PK-INR < = 1.5) and no medical history of
liver cirrhosis or portal hypertension
Exclusion criteria
1. More than 50% of the liver volume (measured by CT or MRI)
replaced by tumor.
2. Evidence of extrahepatic disease by PET-CT
3. Life expectancy of less than four months
4. Pregnant or breast-feeding. Women of childbearing potential
must have a negative pregnancy test performed within seven
days prior to the start of study.
5. Active infection.
6. Ischemic cardiac disease or history of congestive heart failure
with an LVEF < 40%.
7. COPD or other chronic pulmonary disease with PFT’s indicating
an FEV < 50% predicted for age.
8. Reduced renal function defined as s-creatinine > =1.5 × ULN
or creatinine clearance < 40 mL/min, calculated using the
Cockroft and Gault formula.
9. Reduced blood leukocytes or platelets defined as LPK
< 2.0 × 109/L and TPK <100 × 109/L
10. Use of live vaccines four weeks before or after the start
of study.
11. Body mass index above 35.
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Inclusion criteria
1. Male or female aged above 18 years.
2. Signed and dated written informed consent before
the start of specific protocol procedures.
3. Liver metastases measurable by magnetic resonance
imaging (MRI, preferred) or a computational
tomography (CT) scan of thorax and abdomen
according to Response Evaluation Criteria in Solid
Tumors (RECIST) criteria version 1.1 with at least
one unidimensional measurable lesion ≥ 10 mm. The
examination should be within four weeks prior to
randomization.
4. Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1.5. No previous chemotherapy, radiotherapy, or biologic
therapy for uveal melanoma metastases (first-line
therapy).
6. Adequate hepatic function (defined as aspartate
aminotransferase (AST), alanine aminotransferase
(ALT), bilirubin < = 3 times upper limit of normal
(ULN) and prothrombin time international
normalized ratio (PT-INR) < = 1.5) and no medical
history of liver cirrhosis or portal hypertension.
Exclusion criteria
1. More than 50% of the liver volume (measured by
CT or MRI) replaced by tumor.
2. Evidence of extrahepatic disease by Positron emission
tomography–computed tomography (PET-CT).
3. Life expectancy of less than four months.
4. Pregnant or breast-feeding. Women of childbearing
potential must have a negative pregnancy test per-
formed within seven days prior to the start of study.
5. Active infection.
6. Ischemic cardiac disease or history of congestive
heart failure with an Left Ventricular Ejection
Fraction (LVEF) < 40%.
7. Chronic obstructive pulmonary disease (COPD) or
other chronic pulmonary disease with pulmonary
function tests indicating a forced expiratory volume
(FEV) < 50% predicted for age.
8. Reduced renal function defined as s-creatinine
> =1.5 × ULN or creatinine clearance < 40 mL/min,
calculated using the Cockroft and Gault formula.
9. Reduced blood leukocytes or platelets defined as a
leucocyte count < 2.0 × 109/L and a platelet count
<100 × 109/L
10. Use of live vaccines four weeks before or after the
start of study.
11. Body mass index above 35.
Arm A: isolated hepatic perfusion (IHP)
Patients will be treated with IHP at Sahlgrenska University
Hospital, Göteborg, Sweden. The procedure is performed
under general anaesthesia. An L-shaped midline incision
extended under the right hypochondrium is made and
the intrahepatic tumor volume, as well as signs of extra
hepatic spread, is evaluated. Wire reinforced catheters
(Medtronic Inc, Minnesota, USA) are inserted into the
iliac vein and the axillary vein and connected to an ex-
ternal centrifugal pump (Maquet, Jostra Medizintechnik
AG, Hirrlingen, Germany) to allow for shunting of
blood from the lower extremities during the procedure
when the caval vein is clamped. The caval vein is isolated
infrahepatically above the renal veins and suprahepatically
between the liver and the diaphragm. The right adrenal
vein is clamped or ligated. Using the right gonadal vein, a
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vein for perfusion outflow. The portal vein is clamped and
the proper hepatic artery is cannulated via the gastroduo-
denal artery. The catheters are then connected to the per-
fusion system. The liver perfusion is performed at a flow
rate of 500 to 1200 ml/min with a target liver temperature
of 40°C. The temperatures are continuously registered
with thermistor probes (Exacon Scientific A/S, Roskilde,
Denmark) placed in the inflow catheter and in the liver
parenchyma. The leakage from the system is continuously
recorded using technetium labelled albumin (Vasculosis
Cis Bio, Gif-Sur-Yvette, France) injected into the perfusion
circuit and measured using scintillation detector placed
over the veno-venous bypass pump. All measurements are
recorded and stored via the MedicView (Systemdata,
Gothenburg, Sweden) computer system. When steady-
state conditions in the perfusion circuit are established,
melphalan (Alkeran, Aspen Europe GmbH, Bad Oldesloe,
Germany) (1 mg/kg bodyweight divided into two doses,
given 30 minutes apart) is added to the perfusion system.
The perfusion is then continued for 60 minutes, after
which the perfusion is discontinued and the liver is
irrigated with Ringer-Acetate (Ringer Acetat, Baxter,
Sweden). The shunts and the perfusion circuit are
disconnected and the catheters are removed. If the
patients progress systemically or in the liver, they will
be treated with BAC (crossover to treatment arm B) but
will be analyzed as being randomized to IHP according to
intention-to-treat principles.
Arm B: best alternative care (BAC)
The treating physician at each study center will decide
the treatment, together with the patient. All available
treatments, including surgery and other experimental
treatments are tolerated, however no crossover to arm A
(IHP) will be allowed.
Follow-up
Patients will be followed actively according to this protocol
for two years at each study center. Study visits will be car-
ried out at each center and performed at baseline and after
3, 6, 12, 18, and 24 months and will include a CT or MRI
scan of the liver (same modality as baseline examination)
and a European Quality of Life Five Dimension Three
Level Scale (EQ-5D-3 L) quality of life questionnaire. Any
further examinations are at the discretion of the treating
doctor.
Endpoints
The primary objective of the study is OS, defined as the
frequency of individuals alive at 24 months.
Secondary objectives include:
Median OS, defined as time from randomization to
death and analyzed using Kaplan-Meier and the log-ranktest. Hepatic PFS, defined as time from randomization
to progression of existing lesions, or appearance of new
lesions, within the liver according to RECIST criteria
(version 1.1) using a CT or MRI scan [20]. Response,
defined as best response according to RECIST criteria
(version 1.1) using a CT or MRI scan [20]. For the BAC
group, best response during the whole follow-up period
of 24 months, for the IHP group, best response until
hepatic progression (the time point when crossover to
the BAC group is allowed). Health economic evaluation,
to be measured by quality-adjusted life year (QALY),
which will be estimated using EQ-5D-3 L at baseline
and at 3, 6, 12, 18, and 24 months. Any serious adverse
event(SAE) or Suspected Unexpected Serious Adverse
Reactions SUSAR that occurs in either of the two
groups will be reported.
Sample size calculation
It is expected that the percentage of subjects who reach
the primary endpoint of OS after 24 months will be 50%
in the study group and 20% in the control group. Based on
this assumption, 78 subjects are planned to be randomized
to the two treatment groups in a 1:1 ratio (IHP:BAC) to
achieve 80% power for the superiority comparison (Fisher’s
exact test) of the primary endpoint between the two
treatment groups. This allows for a two-sided type I
error of 5% and a 5% dropout rate. Enrolment will con-
tinue until the required sample size has been randomized;
a 60-month recruitment time is expected.
Data monitoring committee (DMC)
An independent Data Monitoring Committee (DMC) will
be appointed and will consist of one physician and one stat-
istician, neither with any other involvement in the study.
For efficacy the DMC should use Ó’Brian-Flemming group
sequential boundaries. The DMC should also look for safety
and at conditional power when giving advice regarding the
continuation of the study. The DMC should start assessing
efficacy data after 40% of the subjects have completed
the study.
Biobanking
Tumor biopsies will be obtained during IHP and these
samples will be used to genetically characterize the tumors
by DNA and RNA sequencing, and to develop mouse
xenograft models. We will also collect blood samples from
all patients at different predefined time points and these
samples will be analyzed for biomarkers using biased
ELISA methods or unbiased proteomics approaches.
Discussion
IHP using melphalan is a major surgical procedure with
associated risks. This procedure was implemented in the
1980s at Sahlgrenska University Hospital, Gothenburg,
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IHP procedure has improved by sequential changes in
the treatment protocol. Before 2005 there was a high
frequency of postoperative mortality, however after
excluding patients with a high tumor burden and by
lowering the melphalan dose to 1 mg/kg bodyweight,
there has been no mortality in more than 50 patients
treated since 2005 [14,15].
Liver insufficiency due to IHP has predominantly been
reported in patients with a high tumor burden (above
50% of the liver volume), and these patients are excluded
from this study. This side effect is an acute toxicity and
will be detected during the immediate postoperative
period (within five days) by daily monitoring of liver
function tests (LFTs).
The current morbidity related to the procedure has been
attributed to complications of the surgical intervention
itself, in particular postoperative infections and thrombo-
embolic events. To reduce this risk, patients receive pre-
operative prophylaxis with antibiotics, as well as a 10-day
prophylactic regimen of low-molecular weight heparin
postoperatively. During the study, SAE will be reported
for both treatment arms, except for events commonly
related to cancer disease. For patients treated with IHP, all
AE grade III to V will also be recorded. The DMC will per-
form safety analyses during the study and can recommend
discontinued inclusion in the study to the steering group.
Taken together, there is a risk to undergoing IHP that
could be compared to other major surgeries (such as
liver resections) with associated complications and a small
risk of postoperative mortality. However, for this group of
patients with a short expected survival and no standard
treatment option, the possible advantages of improved
survival are considered to outweigh the risks.
This group of patients (with liver metastases of ocular
melanoma origin) has a dismal prognosis and no proven
therapy exists that prolongs survival. The median survival
is between six and 12 months and there are very few
patients that can be considered long-term survivors (three
to five years). In a retrospective study IHP has shown a
prolonged OS of 14 months (median) compared to the
longest surviving patients in Sweden during the same time
period [15]. A sample size calculation based on these data,
and with a power of 80% to detect a superiority in the
primary endpoint, has shown that 78 patients are required
to participate in the study.
One weakness of the trial is the limited amount of
patients included, but with a rare disease it is important
to balance the effect size with the possibility of conducting
the trial at all. IHP is a complex procedure, and a survival
benefit of a few weeks or months is probably not clinically
relevant, and this partly justifies the risk of a negative
result even if there would be a small gain in survival not
detected by an underpowered trial.The fields of targeted therapies and immunotherapies
are rapidly evolving and the expected recruitment period
of the study is five years. To avoid the control regimen
becoming obsolete (due to other competing trials) and
recruitment being halted, we have decided that BAC
(including other experimental treatments) will be the
control regimen. As patients in the IHP arm are also
allowed to receive BAC after progression, this study will
evaluate if IHP adds survival time to the best alternative
treatment available during the study period.
Uveal melanoma most frequently carry mutations in the
GNAQ, GNA11, and BAP1 genes, where GNAQ/GNA11
mutations are mutually exclusive [21-23]. With the gen-
etic information obtained from the material in our IHP
biobank, we can investigate if different mutations impact
response rates or OS. It is possible, and even likely, that
knowing the mutation status of the tumor sample would
impact the treatment in arm B upon crossover. However,
we do not believe that this means better systemic treat-
ments for patients randomized to arm B, since it is antici-
pated that mutation analyses affecting treatment decisions
will be undertaken for all patients in the study. RNA
sequencing can also generate expression signatures that
correlate with different survival outcomes. Another
benefit of biobanking blood and tumor tissue is that
new animal models of uveal melanoma can be developed,
and that an increased knowledge concerning biomarkers
of response can be acquired.
Trial status
The study began enrolment in June 2013.
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